2/18/2024 0 Comments Aaron cox horizon therapeutics![]() HORIZON THERAPEUTICS PUBLIC LIMITED COMPANY AMENDED AND RESTATED 2020 EQUITY INCENTIVE PLAN Horizon Therapeutics plc Reports First-Quarter 2022 Financial Results First-Quarter 2022 Results: - Net Sales of $885.2 Million - GAAP Net Income of $204.3 Million Adjusted EBITDA of $371.2 Million - TEPEZZA® (teprotumumab-trbw) Net Sales of $50 Horizon Therapeutics plc Reports Second-Quarter 2022 Financial Results and Revises Full-Year 2022 Net Sales and Adjusted EBITDA Guidance Second-Quarter 2022 Results: - Net Sales of $876.4 Million Orphan Segment Net Sales Increased 13% to $841.3 Mill ![]() Horizon Therapeutics plc Reports Third-Quarter 2022 Financial Results Increases Full-Year 2022 Net Sales and Adjusted EBITDA Guidance Increases TEPEZZA and KRYSTEXXA Peak Annual Net Sales Expectations Third-Quarter 2022 Results: - Net Sales of $925 to be implemented by way of a scheme of arrangement under Chapter 1 of Part 9 of the Companies Act 2014 RECOMMENDED CASH OFFER HORIZON THERAPEUTICS PLC Pillartree Limited, a newly formed private limited company wholly owned by Amgen Inc. Horizon Therapeutics plc Reports Fourth-Quarter and Full-Year 2022 Financial Results Fourth-Quarter 2022 Results: - Net Sales of $942.0 Million - GAAP Net Income of $120.4 Million Adjusted EBITDA of $357.5 Million Includes $37.3 Million of Acquir Horizon Therapeutics plc Reports First-Quarter 2023 Financial Results First-Quarter 2023 Results: - Net Sales of $832.1 Million - GAAP Net Income of $54.7 Million Adjusted EBITDA of $232.9 Million - TEPEZZA® (teprotumumab-trbw) Net Sales of $405 My next educational pit stop after I finish my MRA at Penn in 2024 is to (eventually) pursue a PhD in Health Services Research and Policy.Horizon Therapeutics plc Reports Second-Quarter 2023 Financial Results Second-Quarter 2023 Results: - Net Sales of $945.0 Million, Representing Year-Over-Year Growth of 11% Excluding Inflammation Medicines - GAAP Net Income of $127.1 Million Adjus I have a Master of Public Health in Community Health and Prevention (2019) and a Certificate in Healthcare Informatics (2020) from Drexel University and a Dual Bachelor of Arts in Sociology and Anthropology from Millersville University (2017). Prior to coming to Penn in August 2022, I had two years of regulatory affairs experience at the Jefferson Clinical Research Institute at Thomas Jefferson University. Good clinical practice and good documentation can only happen if we support the physical and mental health of our workforce! This interest also includes research into improving the well-being of clinical research professionals who, let us face it, are experiencing record burnout during this pandemic era. My long-term goal is to develop policy innovations that promote good clinical practice and good documentation practice in the human subjects research setting. Interests / Specialties: I am a Regulatory Affairs Specialist in the Department of Dermatology and a Master of Regulatory Affairs student in the Clinical Research Track at the Perelman School of Medicine at the University of Pennsylvania.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |